Evidence map›Paper›PMID 40786894›Full record

ArticleJournal of hepatocellular carcinoma2025

Yu-De Chu, Pei-Huan Ho, Wei-Ting Chen, Yu-Lin Shih, Ming-Wei Lai, Chao-Wei Hsu, Chau-Ting Yeh

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal of Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-De Chu *Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Pei-Huan Ho *Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Wei-Ting Chen *Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Yu-Lin ShihLiver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Ming-Wei LaiDepartment of Hepatology and Gastroenterology, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Chao-Wei HsuLiver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.
Chau-Ting YehLiver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.ORCID 0000-0001-7376-275X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Surgical resection is the primary curative treatment for hepatocellular carcinoma (HCC), while high recurrence rates can limit the prognosis, emphasizing the need for reliable biomarkers. Patients and Methods: We included 345 HCC patients underwent surgical resection: 15 in the exploration cohort and 330 in the validation cohort. Genome-wide association study (GWAS) and PCR-based genotyping identified SNPs in linkage disequilibrium (LD) with rs9679162. The link between Results: GWAS identified 39 SNP loci linked to rs9679162 and associated with postoperative prognosis. In the validation cohort, 10 SNPs were selected and categorized into four groups. Eight SNPs showed strong LD with rs9679162 and were significantly associated with recurrence-free survival and metastasis-free survival. The predictive performance of the combined SNP groups surpassed that of rs9679162 alone, with the most effective stratification achieved by combining groups-2+3. Additionally, Conclusion: An SNP panel in LD with rs9679162, particularly from group-2 (rs62140629, rs4952033, rs56284247) and group-3 (rs9679162, rs6752303), serves as a prognostic marker for HCC. GALNT14 expression was associated with M2-macrophages, suggesting an immune-regulatory mechanism.

Indexed as

genetic biomarkerhepatocellular carcinomapersonalized medicineSNP paneltumor-infiltrating macrophage

Identifiers

PMID40786894
PMCPMC12333627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.